Lineage Cell Therapeutics to Present at the Maxim Group 2024 Virtual Healthcare SummitBusiness Wire • 10/14/24
OpRegen® (RG6501) Phase 1/2a Results to Be Featured at International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International SymposiumBusiness Wire • 09/25/24
Lineage Presents Preclinical Data on Its Auditory Neuronal Cell Transplant Program, ReSonance™, at the 59th Annual Inner Ear Biology WorkshopBusiness Wire • 09/18/24
Lineage Cell Therapeutics to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual ConferenceBusiness Wire • 08/13/24
Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business UpdateBusiness Wire • 08/08/24
Lineage Cell Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024Business Wire • 08/01/24
Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor SymposiumBusiness Wire • 05/21/24
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateBusiness Wire • 05/09/24
OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation SummitBusiness Wire • 05/06/24
Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024Business Wire • 05/02/24
Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM)Business Wire • 04/30/24
Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate DevelopmentBusiness Wire • 04/01/24
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor SymposiumBusiness Wire • 03/18/24
RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation SummitBusiness Wire • 03/13/24
RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology MeetingBusiness Wire • 03/11/24
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateBusiness Wire • 03/07/24